Abstract:We read with great interest the meta-analysis by Du et al. [1] that assessed the efficacy and safety of a new oral phosphodiesterase type 5 inhibitors (PDE5-Is), mirodenafil, for patients with erectile dysfunction (ED). The meta-analysis identified three randomized controlled trials (RCTs) [2–4] including 374 participants and concluded that mirodenafil is effective and well-tolerated therapy for ED. However, the main issue needed to be addressed is that whether it is reasonable to simply integrate data from the three RCTs. Participants in one trial [3] are ED patients who are taking antihypertensive medications at the same time, which is quite different from another two trials [2,4]. When we tried to find out whether the trial by Paick et al. [3] met the inclusion criteria of this meta-analysis, we found that the inclusion criteria cared more about the patients. However, inclusion criteria for meta-analysis should be focused more on study, which means studies that meet the inclusion criteria and are included in the meta-analysis but not the patients [5]. ED has a multifactorial etiology and PDE5-Is are widely used to treat the disease. However, certain types of antihypertensive agents are likely to affect the efficacy of PDE5-Is in ED patients and even antihypertensive drug itself can impact some aspects of sexual function [6–8]. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers and alphablockers are less likely to cause ED while thiazide diuretics and some less selective beta-blockers (atenolol and carvedilol) may be detrimental to ED [9]. Antihypertensive medications used in Paick’s trial included almost all types and near half of subjects in the trial took more than two types of antihypertensive drug to control their blood pressure. Hence, conclusion from the trial can only be for the ED patients taking antihypertensive medication. Meanwhile, integrating data from the three trials in this meta-analysis seems to be unreasonable and might overestimate the efficacy of mirodenafil for ED patients.

Re: Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials

Correction: Divergent Modulation of Pain and Anxiety by GABAergic Neurons in the Ventrolateral Periaqueductal Gray and Dorsal Raphe.

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7

Evolutionarily Divergent Extradiol Dioxygenases Possess Higher Specificities for Polychlorinated Biphenyl Metabolites

Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies That Target Nav1.7 : Differential Activities of Nav1.7-targeting Monoclonal Antibodies.

Potent and selective repression of by engineered zinc finger repressors for the treatment of neuropathic pain

2-Aminopyridines as Potent and Selective Na v 1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model

Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats

Identification of N-(((1S,3R,5S)-adamantan-1-yl)methyl)-3-((4-chlorophenyl)sulfonyl)benzenesulfonamide as novel Nav1.8 inhibitor with analgesic profile

Combining individual patient data and aggregate data in mixed treatment comparison meta‐analysis: Individual patient data may be beneficial if only for a subset of trials

Nav1.7 Modulator Bearing a 3-Hydroxyindole Backbone Holds the Potential to Reverse Neuropathic Pain

Drug discovery targeting Nav1.8: Structural insights and therapeutic potential

Discovery of E0199: A Novel Compound Targeting Both Peripheral NaV and KV7 Channels to Alleviate Neuropathic Pain

Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain

Small molecule targeting NaV1.7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model

Sodium Channel Inhibitors (Nav1.7, 1.8, And 1.9) For Neuropathic Pain Management

Activation of Neuronal Voltage-Gated Potassium Kv7/KCNQ/M-Current by a Novel Channel Opener SCR2682 for Alleviation of Chronic Pain

Gonadal development and associated changes in liver size and sexual steroids during the reproductive cycle of captive male and female Atlantic cod (Gadus morhua L.).

Effects of tap water iontophoresis and psychological techniques on psychosocial aspects of primary palmar hyperhidrosis.

A Novel Antigen Design Strategy to Isolate Single‐Domain Antibodies that Target Human Nav1.7 and Reduce Pain in Animal Models

Activation of Neuronal Voltage-Gated Potassium Kv7/KCNQ/M-Current by a Novel Channel Opener SCR2682 for Alleviation of Chronic Pain.